| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 33 | 2025 | 266 | 8.620 |
Why?
|
| Liver Transplantation | 26 | 2025 | 1124 | 4.520 |
Why?
|
| Liver Diseases | 17 | 2024 | 389 | 4.030 |
Why?
|
| Diarrhea | 13 | 2025 | 339 | 3.520 |
Why?
|
| Cholera | 8 | 2025 | 30 | 3.400 |
Why?
|
| Mucosal-Associated Invariant T Cells | 5 | 2024 | 6 | 3.350 |
Why?
|
| Hypertension, Portal | 8 | 2022 | 81 | 3.010 |
Why?
|
| Thrombolytic Therapy | 7 | 2024 | 214 | 2.890 |
Why?
|
| Travel | 5 | 2022 | 125 | 2.600 |
Why?
|
| Liver Cirrhosis | 19 | 2025 | 947 | 2.570 |
Why?
|
| Hepatitis C, Chronic | 9 | 2025 | 371 | 2.550 |
Why?
|
| Pulmonary Embolism | 6 | 2024 | 190 | 2.450 |
Why?
|
| Elasticity Imaging Techniques | 7 | 2024 | 141 | 2.410 |
Why?
|
| Vibrio cholerae | 5 | 2025 | 29 | 2.250 |
Why?
|
| Antibodies, Bacterial | 9 | 2025 | 401 | 2.230 |
Why?
|
| Antiviral Agents | 10 | 2025 | 824 | 1.960 |
Why?
|
| Fibrinolytic Agents | 5 | 2024 | 209 | 1.840 |
Why?
|
| Child | 77 | 2025 | 25868 | 1.660 |
Why?
|
| Hepatitis B | 4 | 2016 | 172 | 1.660 |
Why?
|
| Alagille Syndrome | 3 | 2022 | 48 | 1.660 |
Why?
|
| Cholestasis | 4 | 2022 | 157 | 1.610 |
Why?
|
| Liver | 16 | 2025 | 1860 | 1.540 |
Why?
|
| Humans | 153 | 2025 | 133373 | 1.530 |
Why?
|
| Gastroenteritis | 3 | 2024 | 366 | 1.520 |
Why?
|
| Hepatitis B Vaccines | 3 | 2016 | 45 | 1.420 |
Why?
|
| Child, Preschool | 47 | 2025 | 14873 | 1.420 |
Why?
|
| Immunosuppressive Agents | 5 | 2025 | 679 | 1.330 |
Why?
|
| Thrombectomy | 3 | 2024 | 108 | 1.300 |
Why?
|
| Hepatitis B virus | 3 | 2015 | 140 | 1.250 |
Why?
|
| Sirolimus | 2 | 2025 | 239 | 1.190 |
Why?
|
| Esophageal and Gastric Varices | 4 | 2022 | 79 | 1.160 |
Why?
|
| Sofosbuvir | 2 | 2025 | 21 | 1.160 |
Why?
|
| End Stage Liver Disease | 4 | 2025 | 206 | 1.140 |
Why?
|
| Gastroenterology | 4 | 2024 | 205 | 1.110 |
Why?
|
| Weather | 2 | 2024 | 14 | 1.100 |
Why?
|
| Vibrio cholerae O1 | 3 | 2022 | 3 | 1.100 |
Why?
|
| Travel Medicine | 2 | 2018 | 2 | 1.080 |
Why?
|
| Infant | 37 | 2025 | 13243 | 1.040 |
Why?
|
| Aspartate Aminotransferases | 5 | 2024 | 86 | 1.030 |
Why?
|
| Graft Rejection | 3 | 2025 | 566 | 1.010 |
Why?
|
| Adenovirus Infections, Human | 2 | 2023 | 57 | 0.970 |
Why?
|
| Female | 72 | 2025 | 71503 | 0.950 |
Why?
|
| Male | 67 | 2025 | 65592 | 0.920 |
Why?
|
| Hepatitis C | 3 | 2020 | 387 | 0.910 |
Why?
|
| Biomarkers | 12 | 2024 | 3415 | 0.900 |
Why?
|
| Immunity, Innate | 3 | 2024 | 415 | 0.890 |
Why?
|
| Risk Factors | 20 | 2025 | 10954 | 0.890 |
Why?
|
| Cyclopropanes | 2 | 2025 | 71 | 0.870 |
Why?
|
| Ribavirin | 2 | 2025 | 89 | 0.870 |
Why?
|
| Carbamates | 2 | 2024 | 68 | 0.870 |
Why?
|
| Immunoglobulin G | 10 | 2024 | 790 | 0.860 |
Why?
|
| Hepacivirus | 6 | 2024 | 273 | 0.850 |
Why?
|
| Antibodies, Viral | 5 | 2023 | 1205 | 0.850 |
Why?
|
| Transplant Recipients | 3 | 2021 | 227 | 0.850 |
Why?
|
| Smartphone | 1 | 2023 | 45 | 0.840 |
Why?
|
| Eosinophils | 1 | 2024 | 108 | 0.820 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2023 | 59 | 0.820 |
Why?
|
| Adolescent | 36 | 2025 | 20573 | 0.800 |
Why?
|
| Severity of Illness Index | 14 | 2024 | 3105 | 0.800 |
Why?
|
| Dengue Virus | 1 | 2024 | 134 | 0.790 |
Why?
|
| Dysentery | 1 | 2022 | 5 | 0.790 |
Why?
|
| Dengue | 1 | 2024 | 122 | 0.790 |
Why?
|
| Primary Health Care | 2 | 2020 | 806 | 0.780 |
Why?
|
| Cholera Vaccines | 3 | 2021 | 6 | 0.780 |
Why?
|
| Time Factors | 11 | 2024 | 6544 | 0.780 |
Why?
|
| Burns | 1 | 2023 | 101 | 0.750 |
Why?
|
| Religious Missions | 1 | 2021 | 3 | 0.740 |
Why?
|
| Portal Vein | 3 | 2022 | 91 | 0.740 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2022 | 220 | 0.740 |
Why?
|
| Perioperative Care | 3 | 2021 | 212 | 0.740 |
Why?
|
| Serum Bactericidal Antibody Assay | 1 | 2021 | 1 | 0.730 |
Why?
|
| Sulfonamides | 2 | 2021 | 289 | 0.730 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 96 | 0.720 |
Why?
|
| O Antigens | 4 | 2024 | 12 | 0.720 |
Why?
|
| Colonic Neoplasms | 1 | 2024 | 260 | 0.710 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2022 | 57 | 0.710 |
Why?
|
| Biliary Atresia | 3 | 2022 | 206 | 0.710 |
Why?
|
| Rotavirus Infections | 1 | 2024 | 357 | 0.700 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2020 | 39 | 0.690 |
Why?
|
| Seroepidemiologic Studies | 5 | 2025 | 144 | 0.680 |
Why?
|
| Internationality | 1 | 2021 | 137 | 0.680 |
Why?
|
| Rotavirus | 1 | 2024 | 502 | 0.680 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 11 | 0.670 |
Why?
|
| Uracil | 1 | 2020 | 14 | 0.670 |
Why?
|
| Lactams, Macrocyclic | 1 | 2020 | 19 | 0.670 |
Why?
|
| Treatment Outcome | 25 | 2025 | 13103 | 0.670 |
Why?
|
| Anilides | 1 | 2020 | 58 | 0.660 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 107 | 0.660 |
Why?
|
| Ritonavir | 1 | 2020 | 46 | 0.650 |
Why?
|
| Proline | 1 | 2020 | 80 | 0.650 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 26 | 0.650 |
Why?
|
| Fibrinogen | 1 | 2020 | 163 | 0.640 |
Why?
|
| Lung Transplantation | 3 | 2024 | 337 | 0.630 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2020 | 121 | 0.620 |
Why?
|
| Hepatoblastoma | 4 | 2023 | 183 | 0.620 |
Why?
|
| Bacterial Infections | 1 | 2022 | 329 | 0.610 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 179 | 0.610 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 151 | 0.610 |
Why?
|
| Anticoagulants | 3 | 2022 | 628 | 0.600 |
Why?
|
| Retrospective Studies | 26 | 2025 | 17568 | 0.600 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2018 | 19 | 0.590 |
Why?
|
| Fatty Liver | 3 | 2025 | 215 | 0.590 |
Why?
|
| Mice, Knockout | 2 | 2024 | 3979 | 0.590 |
Why?
|
| Health Behavior | 1 | 2021 | 400 | 0.580 |
Why?
|
| Bangladesh | 8 | 2025 | 36 | 0.580 |
Why?
|
| Neonatal Screening | 4 | 2021 | 193 | 0.580 |
Why?
|
| Prospective Studies | 17 | 2025 | 6582 | 0.570 |
Why?
|
| Hepatitis B Surface Antigens | 3 | 2015 | 54 | 0.570 |
Why?
|
| Liver Neoplasms | 5 | 2023 | 1411 | 0.560 |
Why?
|
| Cytokines | 5 | 2024 | 1378 | 0.550 |
Why?
|
| Waiting Lists | 2 | 2016 | 241 | 0.550 |
Why?
|
| Ultrasonic Therapy | 1 | 2017 | 29 | 0.550 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 85 | 0.540 |
Why?
|
| Telemedicine | 1 | 2023 | 507 | 0.530 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 247 | 0.530 |
Why?
|
| Leptospirosis | 1 | 2016 | 6 | 0.530 |
Why?
|
| Radiography, Interventional | 1 | 2017 | 88 | 0.520 |
Why?
|
| Pediatrics | 6 | 2024 | 1221 | 0.520 |
Why?
|
| Registries | 7 | 2025 | 1581 | 0.520 |
Why?
|
| Adult | 23 | 2025 | 31684 | 0.520 |
Why?
|
| Pancreatic Cyst | 1 | 2016 | 28 | 0.510 |
Why?
|
| Platelet Count | 7 | 2024 | 143 | 0.490 |
Why?
|
| Sepsis | 1 | 2020 | 523 | 0.490 |
Why?
|
| Middle Aged | 19 | 2025 | 28985 | 0.480 |
Why?
|
| Acute Disease | 6 | 2024 | 1184 | 0.480 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2015 | 125 | 0.460 |
Why?
|
| Anti-Bacterial Agents | 9 | 2023 | 2575 | 0.460 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2015 | 87 | 0.460 |
Why?
|
| Gastrointestinal Diseases | 3 | 2025 | 353 | 0.450 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 129 | 0.440 |
Why?
|
| Biopsy | 5 | 2025 | 1204 | 0.440 |
Why?
|
| Leg | 1 | 2015 | 142 | 0.440 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 683 | 0.440 |
Why?
|
| Weight Gain | 1 | 2017 | 412 | 0.440 |
Why?
|
| Shigella Vaccines | 2 | 2024 | 2 | 0.440 |
Why?
|
| Dysentery, Bacillary | 2 | 2024 | 12 | 0.440 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2025 | 135 | 0.430 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2022 | 244 | 0.430 |
Why?
|
| Hepatitis B Antibodies | 1 | 2013 | 24 | 0.430 |
Why?
|
| Drug Therapy, Combination | 4 | 2025 | 1165 | 0.430 |
Why?
|
| Fever | 3 | 2024 | 312 | 0.430 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2020 | 359 | 0.420 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 47 | 0.420 |
Why?
|
| Young Adult | 11 | 2025 | 9923 | 0.420 |
Why?
|
| Urea Cycle Disorders, Inborn | 3 | 2025 | 85 | 0.420 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 288 | 0.420 |
Why?
|
| Growth Disorders | 3 | 2023 | 225 | 0.410 |
Why?
|
| BCG Vaccine | 2 | 2025 | 112 | 0.410 |
Why?
|
| Postoperative Complications | 5 | 2025 | 3171 | 0.410 |
Why?
|
| Africa | 2 | 2024 | 140 | 0.410 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2019 | 60 | 0.410 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 126 | 0.410 |
Why?
|
| Infant, Newborn | 13 | 2025 | 8632 | 0.410 |
Why?
|
| Asia | 3 | 2023 | 125 | 0.400 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 82 | 0.390 |
Why?
|
| Adenoviruses, Human | 2 | 2023 | 99 | 0.380 |
Why?
|
| Bayes Theorem | 2 | 2025 | 310 | 0.380 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2025 | 35 | 0.370 |
Why?
|
| Ischemia | 1 | 2015 | 382 | 0.370 |
Why?
|
| Models, Statistical | 2 | 2024 | 500 | 0.360 |
Why?
|
| Immunoglobulin M | 5 | 2024 | 217 | 0.360 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2025 | 202 | 0.350 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2022 | 108 | 0.350 |
Why?
|
| Epidemiological Monitoring | 2 | 2021 | 63 | 0.340 |
Why?
|
| Food Contamination | 3 | 2020 | 29 | 0.340 |
Why?
|
| United States | 9 | 2025 | 11722 | 0.330 |
Why?
|
| Body Height | 3 | 2017 | 228 | 0.330 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 822 | 0.330 |
Why?
|
| Feces | 4 | 2022 | 783 | 0.330 |
Why?
|
| Graft Survival | 3 | 2025 | 482 | 0.330 |
Why?
|
| Argininosuccinate Lyase | 2 | 2021 | 65 | 0.330 |
Why?
|
| Genotype | 4 | 2024 | 2720 | 0.330 |
Why?
|
| Alanine Transaminase | 2 | 2020 | 162 | 0.330 |
Why?
|
| Cohort Studies | 11 | 2024 | 5199 | 0.320 |
Why?
|
| Prevalence | 6 | 2025 | 2632 | 0.320 |
Why?
|
| Ultrasonography | 6 | 2021 | 999 | 0.320 |
Why?
|
| Vaccines, Conjugate | 3 | 2024 | 83 | 0.310 |
Why?
|
| Dysbiosis | 2 | 2021 | 145 | 0.310 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 723 | 0.310 |
Why?
|
| Aged | 10 | 2024 | 21500 | 0.310 |
Why?
|
| Hepatomegaly | 1 | 2009 | 22 | 0.310 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 5443 | 0.300 |
Why?
|
| Drug Combinations | 3 | 2025 | 284 | 0.300 |
Why?
|
| Utah | 3 | 2025 | 83 | 0.300 |
Why?
|
| Failure to Thrive | 1 | 2009 | 93 | 0.290 |
Why?
|
| Nutritional Status | 4 | 2021 | 328 | 0.290 |
Why?
|
| Vaccines, Inactivated | 2 | 2022 | 148 | 0.280 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 429 | 0.280 |
Why?
|
| Shigella flexneri | 2 | 2024 | 16 | 0.280 |
Why?
|
| Prognosis | 5 | 2024 | 5044 | 0.280 |
Why?
|
| Vegetables | 2 | 2020 | 273 | 0.270 |
Why?
|
| Mass Screening | 1 | 2013 | 837 | 0.270 |
Why?
|
| STAT1 Transcription Factor | 2 | 2025 | 77 | 0.270 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 3740 | 0.270 |
Why?
|
| Veterinary Drugs | 2 | 2018 | 3 | 0.270 |
Why?
|
| Immunoglobulin A | 3 | 2021 | 215 | 0.270 |
Why?
|
| Disease Management | 3 | 2022 | 565 | 0.270 |
Why?
|
| Body Weight | 3 | 2017 | 1035 | 0.270 |
Why?
|
| Propensity Score | 2 | 2020 | 263 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2020 | 3718 | 0.250 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 305 | 0.250 |
Why?
|
| Hemorrhage | 2 | 2020 | 519 | 0.250 |
Why?
|
| Fibrosis | 3 | 2023 | 428 | 0.250 |
Why?
|
| Democratic Republic of the Congo | 1 | 2025 | 16 | 0.250 |
Why?
|
| Milk | 2 | 2018 | 123 | 0.250 |
Why?
|
| Aminophenols | 1 | 2025 | 9 | 0.240 |
Why?
|
| Benzodioxoles | 1 | 2025 | 10 | 0.240 |
Why?
|
| Pyrrolidines | 2 | 2025 | 42 | 0.240 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2025 | 39 | 0.230 |
Why?
|
| Animals | 11 | 2024 | 36222 | 0.230 |
Why?
|
| Herpes Labialis | 1 | 2004 | 2 | 0.230 |
Why?
|
| Fatty Alcohols | 1 | 2004 | 7 | 0.230 |
Why?
|
| Rural Health Services | 1 | 2025 | 28 | 0.230 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2024 | 9 | 0.230 |
Why?
|
| Suction | 2 | 2024 | 56 | 0.230 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 385 | 0.230 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 395 | 0.230 |
Why?
|
| Herpesvirus 1, Human | 1 | 2004 | 34 | 0.230 |
Why?
|
| Paracentesis | 1 | 2024 | 21 | 0.220 |
Why?
|
| Receptors, Transferrin | 1 | 2024 | 14 | 0.220 |
Why?
|
| Frameshift Mutation | 1 | 2025 | 201 | 0.220 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 182 | 0.220 |
Why?
|
| Endovascular Procedures | 2 | 2024 | 783 | 0.220 |
Why?
|
| Disease Progression | 3 | 2020 | 2246 | 0.220 |
Why?
|
| Benzimidazoles | 2 | 2024 | 136 | 0.220 |
Why?
|
| Incidence | 3 | 2025 | 3395 | 0.220 |
Why?
|
| Community Health Workers | 1 | 2025 | 77 | 0.220 |
Why?
|
| Climate | 1 | 2024 | 24 | 0.220 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 7141 | 0.220 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 47 | 0.220 |
Why?
|
| Chloride Channel Agonists | 2 | 2025 | 5 | 0.220 |
Why?
|
| Indoles | 1 | 2025 | 202 | 0.220 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 35 | 0.220 |
Why?
|
| Hospitals, Pediatric | 1 | 2009 | 795 | 0.210 |
Why?
|
| Gastrostomy | 1 | 2024 | 92 | 0.210 |
Why?
|
| Pesticide Residues | 2 | 2020 | 5 | 0.210 |
Why?
|
| Reproducibility of Results | 5 | 2025 | 3043 | 0.210 |
Why?
|
| Rotavirus Vaccines | 1 | 2024 | 73 | 0.210 |
Why?
|
| Loss of Function Mutation | 1 | 2025 | 162 | 0.210 |
Why?
|
| Shigella | 1 | 2023 | 4 | 0.210 |
Why?
|
| Coculture Techniques | 1 | 2024 | 245 | 0.210 |
Why?
|
| Enterobacteriaceae | 1 | 2023 | 41 | 0.210 |
Why?
|
| beta-Lactams | 1 | 2023 | 56 | 0.210 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 3988 | 0.210 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 204 | 0.200 |
Why?
|
| Hemoglobins | 1 | 2024 | 322 | 0.200 |
Why?
|
| Interleukin-33 | 1 | 2023 | 18 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 4823 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2024 | 227 | 0.200 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 24 | 0.200 |
Why?
|
| Endoglin | 1 | 2022 | 32 | 0.200 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 1 | 2022 | 3 | 0.200 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 179 | 0.200 |
Why?
|
| Orthomyxoviridae | 1 | 2022 | 52 | 0.200 |
Why?
|
| Frailty | 1 | 2025 | 134 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2025 | 334 | 0.190 |
Why?
|
| Cough | 2 | 2020 | 96 | 0.190 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2025 | 545 | 0.190 |
Why?
|
| Paramyxoviridae Infections | 1 | 2022 | 49 | 0.190 |
Why?
|
| Germ-Line Mutation | 1 | 2025 | 368 | 0.190 |
Why?
|
| Agammaglobulinemia | 1 | 2022 | 44 | 0.190 |
Why?
|
| Enzyme Replacement Therapy | 2 | 2021 | 17 | 0.190 |
Why?
|
| Antigens, CD | 1 | 2024 | 441 | 0.190 |
Why?
|
| Pericarditis | 1 | 2022 | 43 | 0.190 |
Why?
|
| Wechsler Scales | 1 | 2022 | 20 | 0.190 |
Why?
|
| Hepatitis | 1 | 2022 | 57 | 0.190 |
Why?
|
| Sensitivity and Specificity | 6 | 2025 | 2142 | 0.190 |
Why?
|
| Osteomyelitis | 1 | 2025 | 214 | 0.190 |
Why?
|
| Varicose Veins | 1 | 2022 | 31 | 0.190 |
Why?
|
| Jet Lag Syndrome | 1 | 2021 | 1 | 0.190 |
Why?
|
| Sunburn | 1 | 2021 | 4 | 0.190 |
Why?
|
| Age Factors | 3 | 2015 | 2956 | 0.190 |
Why?
|
| Lymphocyte Activation | 1 | 2024 | 687 | 0.190 |
Why?
|
| Genes, X-Linked | 1 | 2022 | 64 | 0.180 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2021 | 32 | 0.180 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2023 | 211 | 0.180 |
Why?
|
| Ownership | 1 | 2022 | 36 | 0.180 |
Why?
|
| Interleukin-8 | 1 | 2022 | 214 | 0.180 |
Why?
|
| Recurrence | 2 | 2016 | 1469 | 0.180 |
Why?
|
| Duodenum | 1 | 2022 | 97 | 0.180 |
Why?
|
| Birds | 1 | 2022 | 87 | 0.180 |
Why?
|
| Luminescent Measurements | 1 | 2021 | 60 | 0.180 |
Why?
|
| Phenotype | 2 | 2022 | 4577 | 0.180 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 498 | 0.180 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2022 | 70 | 0.180 |
Why?
|
| Respiratory Tract Diseases | 1 | 2022 | 81 | 0.180 |
Why?
|
| Insect Repellents | 1 | 2021 | 36 | 0.180 |
Why?
|
| Patient Readmission | 1 | 2025 | 430 | 0.180 |
Why?
|
| beta-Lactamases | 1 | 2023 | 212 | 0.180 |
Why?
|
| Quinoxalines | 1 | 2021 | 40 | 0.180 |
Why?
|
| Iron | 1 | 2024 | 304 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 322 | 0.180 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2021 | 8 | 0.180 |
Why?
|
| Myocarditis | 1 | 2022 | 133 | 0.180 |
Why?
|
| Genes, Recessive | 1 | 2022 | 195 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 344 | 0.180 |
Why?
|
| Peroxidase | 1 | 2021 | 65 | 0.180 |
Why?
|
| Hepatitis E virus | 1 | 2020 | 4 | 0.170 |
Why?
|
| Hepatitis E | 1 | 2020 | 5 | 0.170 |
Why?
|
| Mice | 6 | 2024 | 18936 | 0.170 |
Why?
|
| Iliac Vein | 1 | 2021 | 30 | 0.170 |
Why?
|
| Fruit | 2 | 2020 | 235 | 0.170 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 584 | 0.170 |
Why?
|
| Malaria | 1 | 2021 | 104 | 0.170 |
Why?
|
| Femoral Vein | 1 | 2021 | 49 | 0.170 |
Why?
|
| Geography, Medical | 1 | 2020 | 16 | 0.170 |
Why?
|
| 2-Naphthylamine | 1 | 2020 | 6 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 321 | 0.170 |
Why?
|
| Clinical Coding | 1 | 2020 | 15 | 0.170 |
Why?
|
| Case-Control Studies | 5 | 2020 | 3418 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 45 | 0.170 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2020 | 4 | 0.170 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 76 | 0.170 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2021 | 64 | 0.170 |
Why?
|
| Tablets | 1 | 2020 | 36 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2023 | 536 | 0.170 |
Why?
|
| Flow Cytometry | 1 | 2023 | 815 | 0.170 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 501 | 0.170 |
Why?
|
| Vascular Patency | 1 | 2021 | 198 | 0.170 |
Why?
|
| Metagenome | 1 | 2021 | 157 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 173 | 0.170 |
Why?
|
| Parasitic Diseases | 1 | 2021 | 62 | 0.170 |
Why?
|
| Mothers | 1 | 2023 | 373 | 0.170 |
Why?
|
| Logistic Models | 2 | 2015 | 1864 | 0.170 |
Why?
|
| Liver Glycogen | 1 | 2020 | 23 | 0.160 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 114 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 265 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 144 | 0.160 |
Why?
|
| Adenoviridae | 1 | 2023 | 606 | 0.160 |
Why?
|
| Escherichia coli | 2 | 2023 | 1031 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 453 | 0.160 |
Why?
|
| Valine | 1 | 2020 | 115 | 0.160 |
Why?
|
| Anthropometry | 2 | 2018 | 205 | 0.160 |
Why?
|
| Genetic Testing | 3 | 2022 | 1101 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 306 | 0.160 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2021 | 151 | 0.160 |
Why?
|
| Skin | 1 | 2023 | 542 | 0.160 |
Why?
|
| Drug Residues | 2 | 2018 | 2 | 0.160 |
Why?
|
| Breast Feeding | 2 | 2022 | 240 | 0.160 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 101 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1340 | 0.160 |
Why?
|
| Ursodeoxycholic Acid | 2 | 2018 | 38 | 0.160 |
Why?
|
| Dyspnea | 1 | 2020 | 160 | 0.150 |
Why?
|
| Health Resources | 1 | 2020 | 127 | 0.150 |
Why?
|
| Viral Vaccines | 1 | 2022 | 345 | 0.150 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2020 | 193 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2021 | 202 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 294 | 0.150 |
Why?
|
| Pesticides | 1 | 2019 | 30 | 0.150 |
Why?
|
| Metabolome | 1 | 2021 | 322 | 0.150 |
Why?
|
| Pandemics | 3 | 2022 | 1193 | 0.150 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 1513 | 0.150 |
Why?
|
| Curriculum | 1 | 2024 | 768 | 0.150 |
Why?
|
| Hospitals | 1 | 2021 | 441 | 0.150 |
Why?
|
| Neoplasms | 1 | 2013 | 2992 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 562 | 0.150 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2018 | 2 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2021 | 180 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 569 | 0.140 |
Why?
|
| Hazard Analysis and Critical Control Points | 1 | 2018 | 1 | 0.140 |
Why?
|
| Hyperplasia | 1 | 2018 | 196 | 0.140 |
Why?
|
| Pseudomonas Infections | 2 | 2019 | 122 | 0.140 |
Why?
|
| Parents | 1 | 2025 | 1073 | 0.140 |
Why?
|
| Barotrauma | 1 | 2018 | 4 | 0.140 |
Why?
|
| Altitude Sickness | 1 | 2018 | 3 | 0.140 |
Why?
|
| Bacteria | 1 | 2022 | 537 | 0.140 |
Why?
|
| Physicians | 1 | 2025 | 640 | 0.140 |
Why?
|
| Ships | 1 | 2018 | 7 | 0.140 |
Why?
|
| Food Safety | 1 | 2018 | 6 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 183 | 0.140 |
Why?
|
| Antibodies | 2 | 2021 | 372 | 0.140 |
Why?
|
| Age Distribution | 1 | 2019 | 427 | 0.140 |
Why?
|
| Aircraft | 1 | 2018 | 22 | 0.140 |
Why?
|
| Desiccation | 1 | 2018 | 46 | 0.140 |
Why?
|
| Zoonoses | 1 | 2018 | 52 | 0.140 |
Why?
|
| Microbiota | 1 | 2023 | 443 | 0.140 |
Why?
|
| Serologic Tests | 1 | 2018 | 128 | 0.140 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2017 | 54 | 0.140 |
Why?
|
| Insect Bites and Stings | 1 | 2018 | 39 | 0.140 |
Why?
|
| Accidents, Traffic | 1 | 2018 | 111 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2018 | 144 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2021 | 1584 | 0.130 |
Why?
|
| Immunity, Mucosal | 1 | 2017 | 94 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 211 | 0.130 |
Why?
|
| Thrombosis | 1 | 2022 | 545 | 0.130 |
Why?
|
| Intestinal Mucosa | 1 | 2022 | 791 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 464 | 0.130 |
Why?
|
| Growth | 1 | 2017 | 106 | 0.130 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2018 | 98 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2019 | 311 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 57 | 0.130 |
Why?
|
| Occupations | 1 | 2016 | 20 | 0.130 |
Why?
|
| Obesity | 1 | 2008 | 2440 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 373 | 0.130 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2017 | 73 | 0.130 |
Why?
|
| Waterborne Diseases | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3794 | 0.130 |
Why?
|
| Japan | 1 | 2016 | 152 | 0.130 |
Why?
|
| Arthritis, Reactive | 1 | 2016 | 5 | 0.130 |
Why?
|
| Survival Rate | 2 | 2019 | 2207 | 0.130 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 12 | 0.130 |
Why?
|
| Salicylates | 1 | 2016 | 47 | 0.120 |
Why?
|
| Antidiarrheals | 1 | 2016 | 19 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2022 | 700 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 1473 | 0.120 |
Why?
|
| Dehydration | 1 | 2016 | 42 | 0.120 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2016 | 31 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1166 | 0.120 |
Why?
|
| Hepatitis D | 1 | 2015 | 3 | 0.120 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2017 | 199 | 0.120 |
Why?
|
| Bismuth | 1 | 2016 | 74 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 4760 | 0.120 |
Why?
|
| Parenteral Nutrition | 1 | 2017 | 199 | 0.120 |
Why?
|
| Critical Care | 1 | 2021 | 698 | 0.120 |
Why?
|
| Lipopolysaccharides | 3 | 2024 | 316 | 0.120 |
Why?
|
| Telecommunications | 1 | 2015 | 22 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 106 | 0.120 |
Why?
|
| Child Development | 2 | 2018 | 286 | 0.120 |
Why?
|
| Pancreas | 1 | 2016 | 231 | 0.120 |
Why?
|
| Birth Weight | 1 | 2017 | 356 | 0.120 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 36 | 0.120 |
Why?
|
| Asthma | 1 | 2023 | 807 | 0.120 |
Why?
|
| Patient Safety | 1 | 2020 | 436 | 0.120 |
Why?
|
| Patient Selection | 1 | 2019 | 734 | 0.110 |
Why?
|
| Fluid Therapy | 1 | 2016 | 149 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 574 | 0.110 |
Why?
|
| Fluoroquinolones | 1 | 2015 | 97 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 129 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2016 | 396 | 0.110 |
Why?
|
| Creatinine | 1 | 2016 | 418 | 0.110 |
Why?
|
| Work | 1 | 2014 | 12 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 3363 | 0.110 |
Why?
|
| Algeria | 2 | 2025 | 2 | 0.110 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2877 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 395 | 0.110 |
Why?
|
| Angioplasty, Balloon | 1 | 2015 | 162 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 772 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2015 | 246 | 0.110 |
Why?
|
| Mercaptopurine | 1 | 2013 | 72 | 0.110 |
Why?
|
| Limit of Detection | 3 | 2019 | 77 | 0.100 |
Why?
|
| Virus Activation | 1 | 2013 | 85 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2015 | 1033 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 313 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2020 | 804 | 0.100 |
Why?
|
| Probiotics | 1 | 2016 | 229 | 0.100 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2016 | 222 | 0.100 |
Why?
|
| Allopurinol | 1 | 2013 | 75 | 0.100 |
Why?
|
| Gestational Age | 1 | 2017 | 1231 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 1001 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 401 | 0.100 |
Why?
|
| Inflammation | 2 | 2020 | 1559 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 606 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 255 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 197 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2024 | 1236 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2013 | 496 | 0.090 |
Why?
|
| Qualitative Research | 2 | 2025 | 658 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1310 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 945 | 0.090 |
Why?
|
| Hepatectomy | 2 | 2023 | 124 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2014 | 281 | 0.090 |
Why?
|
| Pedigree | 2 | 2025 | 1730 | 0.090 |
Why?
|
| Family | 1 | 2014 | 593 | 0.090 |
Why?
|
| Vaccines | 1 | 2016 | 380 | 0.090 |
Why?
|
| Pruritus | 2 | 2022 | 43 | 0.080 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1100 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2015 | 491 | 0.080 |
Why?
|
| Pregnancy | 3 | 2020 | 7602 | 0.080 |
Why?
|
| Glycogen Storage Disease | 1 | 2009 | 9 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2205 | 0.080 |
Why?
|
| Philadelphia | 1 | 2009 | 27 | 0.080 |
Why?
|
| Quality of Life | 3 | 2025 | 2168 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2015 | 1713 | 0.080 |
Why?
|
| Stents | 1 | 2015 | 881 | 0.080 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2009 | 55 | 0.070 |
Why?
|
| ROC Curve | 2 | 2021 | 606 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1973 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2288 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 760 | 0.070 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 237 | 0.070 |
Why?
|
| Hospitalization | 3 | 2021 | 1921 | 0.070 |
Why?
|
| Vaccination | 2 | 2022 | 1019 | 0.060 |
Why?
|
| Cholera Toxin | 2 | 2017 | 51 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 818 | 0.060 |
Why?
|
| Neutropenia | 2 | 2020 | 205 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2025 | 779 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1313 | 0.060 |
Why?
|
| Quinolones | 1 | 2025 | 57 | 0.060 |
Why?
|
| Argininosuccinic Aciduria | 1 | 2025 | 56 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3666 | 0.060 |
Why?
|
| Mycobacterium bovis | 1 | 2025 | 31 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2025 | 58 | 0.060 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2024 | 35 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2022 | 1830 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2004 | 143 | 0.060 |
Why?
|
| Quinolines | 1 | 2025 | 115 | 0.060 |
Why?
|
| Benzopyrans | 1 | 2024 | 21 | 0.060 |
Why?
|
| Serogroup | 1 | 2024 | 63 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2024 | 46 | 0.050 |
Why?
|
| Siblings | 1 | 2025 | 202 | 0.050 |
Why?
|
| Pyridines | 1 | 2025 | 250 | 0.050 |
Why?
|
| Homozygote | 1 | 2025 | 562 | 0.050 |
Why?
|
| South Africa | 1 | 2023 | 127 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 280 | 0.050 |
Why?
|
| Methacholine Chloride | 1 | 2023 | 21 | 0.050 |
Why?
|
| Airway Resistance | 1 | 2023 | 36 | 0.050 |
Why?
|
| Lung | 2 | 2023 | 1571 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 59 | 0.050 |
Why?
|
| Interleukin-5 | 1 | 2023 | 48 | 0.050 |
Why?
|
| Hong Kong | 1 | 2022 | 15 | 0.050 |
Why?
|
| Mali | 1 | 2022 | 12 | 0.050 |
Why?
|
| Catheterization, Peripheral | 1 | 2024 | 132 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2023 | 155 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2023 | 98 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 45 | 0.050 |
Why?
|
| Rural Population | 1 | 2025 | 280 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2025 | 542 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2022 | 18 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 49 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 76 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2022 | 245 | 0.050 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 48 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2024 | 1083 | 0.050 |
Why?
|
| Cats | 1 | 2022 | 119 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 89 | 0.050 |
Why?
|
| Viremia | 1 | 2022 | 134 | 0.050 |
Why?
|
| Bilirubin | 1 | 2022 | 131 | 0.050 |
Why?
|
| Trachea | 1 | 2023 | 212 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2021 | 104 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 404 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2023 | 335 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2022 | 91 | 0.040 |
Why?
|
| Chickens | 1 | 2022 | 639 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2021 | 53 | 0.040 |
Why?
|
| Indigo Carmine | 1 | 2021 | 1 | 0.040 |
Why?
|
| Salmonella typhi | 1 | 2021 | 21 | 0.040 |
Why?
|
| Alloys | 1 | 2021 | 15 | 0.040 |
Why?
|
| Constipation | 1 | 2022 | 128 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2021 | 110 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2023 | 372 | 0.040 |
Why?
|
| Endotoxins | 1 | 2021 | 49 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 200 | 0.040 |
Why?
|
| Travel-Related Illness | 1 | 2020 | 5 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 2021 | 49 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2021 | 44 | 0.040 |
Why?
|
| Hyperammonemia | 1 | 2021 | 62 | 0.040 |
Why?
|
| Dogs | 1 | 2022 | 672 | 0.040 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2021 | 60 | 0.040 |
Why?
|
| Allergens | 1 | 2023 | 279 | 0.040 |
Why?
|
| Acinetobacter baumannii | 1 | 2021 | 47 | 0.040 |
Why?
|
| Klebsiella pneumoniae | 1 | 2021 | 88 | 0.040 |
Why?
|
| India | 1 | 2021 | 239 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 823 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 560 | 0.040 |
Why?
|
| Estrogens | 1 | 2023 | 524 | 0.040 |
Why?
|
| Health Status | 1 | 2022 | 414 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 105 | 0.040 |
Why?
|
| Prednisone | 1 | 2020 | 256 | 0.040 |
Why?
|
| Motivation | 1 | 2022 | 329 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 135 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 1156 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2022 | 199 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 121 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 198 | 0.040 |
Why?
|
| Body Size | 1 | 2020 | 69 | 0.040 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 89 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 719 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2022 | 507 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 568 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 562 | 0.040 |
Why?
|
| Histamine H2 Antagonists | 1 | 2019 | 49 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 237 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2021 | 164 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2019 | 71 | 0.040 |
Why?
|
| Provitamins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cholestyramine Resin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 11 | 0.040 |
Why?
|
| Sudan | 1 | 2018 | 4 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2018 | 26 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2021 | 291 | 0.040 |
Why?
|
| Solid Phase Extraction | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2024 | 3131 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2018 | 34 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2022 | 860 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 663 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 199 | 0.040 |
Why?
|
| beta Carotene | 1 | 2018 | 37 | 0.040 |
Why?
|
| Phosphotransferases (Nitrogenous Group Acceptor) | 1 | 2017 | 1 | 0.030 |
Why?
|
| Vibrio cholerae O139 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Phosphoenolpyruvate Sugar Phosphotransferase System | 1 | 2017 | 7 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 319 | 0.030 |
Why?
|
| Metabolomics | 1 | 2021 | 471 | 0.030 |
Why?
|
| Mutation | 2 | 2023 | 6343 | 0.030 |
Why?
|
| Flagellin | 1 | 2017 | 21 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 480 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 2017 | 89 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 651 | 0.030 |
Why?
|
| Alleles | 1 | 2022 | 1697 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 629 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 964 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2024 | 1070 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 551 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 1583 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2559 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2017 | 273 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1463 | 0.030 |
Why?
|
| Uzbekistan | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 2015 | 6 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 275 | 0.030 |
Why?
|
| Ukraine | 1 | 2015 | 10 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 296 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 356 | 0.030 |
Why?
|
| Fimbriae Proteins | 1 | 2015 | 22 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 938 | 0.030 |
Why?
|
| Sclerotherapy | 1 | 2015 | 41 | 0.030 |
Why?
|
| Ligation | 1 | 2015 | 134 | 0.030 |
Why?
|
| Head | 1 | 2015 | 114 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2015 | 191 | 0.030 |
Why?
|
| Guanine Nucleotides | 1 | 2013 | 14 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1714 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2015 | 180 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 35 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 702 | 0.030 |
Why?
|
| Biotransformation | 1 | 2013 | 56 | 0.030 |
Why?
|
| Thionucleotides | 1 | 2013 | 23 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 105 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 21 | 0.030 |
Why?
|
| Xanthine Oxidase | 1 | 2013 | 39 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 42 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 1676 | 0.030 |
Why?
|
| Endoscopy | 1 | 2015 | 280 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 83 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3869 | 0.020 |
Why?
|
| Methotrexate | 1 | 2013 | 355 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 563 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1240 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 551 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1353 | 0.020 |
Why?
|